

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450

Dolores DeCarminie
Type or print name

Dolores DeCarminie
Signature

5/22/03
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE ISSUED PATENT 6,465,504 OF

RENE LATTMANN ET AL

ISSUED: OCTOBER 15, 2002

APPLICATION NO.: 09/699,765

FILED: OCTOBER 30, 2000

FOR: SUBSTITUTED 3,5-DIPHENYL-1,2,4-
TRIAZOLES AND THEIR USE AS
PHARMACEUTICAL METAL CHELATORSATTENTION: CERTIFICATE OF CORRECTION BRANCHCommissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450REQUEST FOR CERTIFICATE OF CORRECTION UNDER CFR § 1.322

Sir:

Pursuant to 37 CFR 1.322, it is hereby respectfully requested that a Certificate of Correction be issued for United States Patent 6,465,504 containing the corrections set forth on the appended Form PTO 1050.

On the title page, in item (75), the **Inventors'** information was incorrect. The country where the two inventors reside should be **Switzerland** and not Sweden. Also, in item (30), the "**Foreign Application Priority Data**" listed the country where the application was filed incorrectly. The country is also **Switzerland**. Note that the attached copy of the Declaration clearly shows this to be true.

Each of the other errors is believed to be attributable to the Patent and Trademark Office as is evident as shown in the table on page 2:

Case No. 4-209188/N1
 Application No. 09/699,765
 Filing Date: 5/22/03
 Issue Date: _____

Express Mail No.: _____
 The Patent & Trademark Office acknowledges, and has stamped
 upon the date of receipt of the items checked below:

Amendment/Response/Letter - Fee \$ _____

Appln. Filing Papers - Fee \$ _____

- PCT National Stage
- Provisional Application
- RCE DIV CONT
- Specification _____ Pg's

Executed/Unexecuted Decl. - Fee \$ _____

- Missing Parts/Missing Req.

Preliminary Amendment _____ Pg's

Claim of Priority Certified Copy(s)

Amendment After Final

Notice of Appeal - Fee \$ _____

Appeal Brief - Fee \$ _____

Issue Fee Payment \$ _____

Assignment Rec. Req. - Fee \$ _____

Original Drawings _____ Pg's

DS _____ Pg's - Fee \$ _____


PTO-1449 Form _____ Pg's

Ret. for Ext. of Time - Fee \$ _____

Application Data Sheet

Seq. Listings _____ Pg's/Seq. Disk

Request for Certificate of Correction -
 Form PTO-1050 (2) *Encl. Declaration*
 and App. 11, 24, 25, 26, 27
 of Spec. 82972/99A Rev.1
 als



JOSEPH J. BOROVIAN
 NOVARTIS
 CORPORATE INTELLECTUAL PROPERTY
 ONE HEALTH PLAZA, BUILDING 430
 EAST HANOVER, NJ 07936-1080

A request for a Certificate of Correction has
 been received for U.S. Patent 6465504
 4-209188

U.S. DEPARTMENT OF COMMERCE
 PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231

RECEIVED JUN 03 2003
 VA

| | | |
|---|------|-------------|
| PENALTY FOR PRIVATE USE \$1500 | 0023 | * * * |
| HETER H 5050010 | | |

| <u>Location and/or Error in Printed Patent</u> | <u>Location of Support in *Specification or **Amendment</u> |
|---|---|
| Column 7, line 63, replacement of "alkoXY" with "alkoxy" | *Page 11, line 11 beneath the structural formula |
| Column 8, line 10, replacement of "I" with "II" | *Page 11, line 18 beneath the structural formula |
| Column 16, last line, replacement of "1.7 9" with "1.7 g" | *Page 24, third line of Example 18 |
| Column 17, line 17, replacement of "tazole" with "triazole" | *Page 24, fifth line of Example 19 |
| Column 17, line 58, replacement of "268-269-269° C." with "268-269° C." | Page 25, sixth line of Example 21 |
| Column 18, line 24, replacement of "13,5" with "[3,5" | *Page 26, second line of Example 24 |
| Column 19, line 34, replacement of "ace" with "acetamide" | *Page 27, seventh line of Example 29 |
| Column 19, line 42, replacement of "1.09" with "1.0 g" | *Page 27, third line of Example 30 |
| Column 19, line 53, after "4.9 (s,2H)", insertion of "7.0 (m, 4H)" and replacement of "7.4 (m,3H)" with "7.4 (m, 3H)" | *Page 28, line 3 and 4 |

Enclosed are copies of pages 11, 24, 25, 26, 27 and 28, which clearly show the location of support.

Attached is a duplicate of Form PTO 1050, with at least one copy being suitable for printing.

Since the above errors are not ascribable to the patentees, no fee is believed to be necessitated by this Request for Certificate of Correction. However, in the event that a fee is required, the Commissioner is hereby authorized to charge said fee to Deposit Account No. 19-0134 in the name of Novartis.

Please send the Certificate of Correction to the address currently associated with Customer No. 001095, viz:

Thomas Hoxie
Novartis
Corporate Intellectual Property
One Health Plaza – Building 430
East Hanover, NJ 07936-1080


Respectfully submitted,

Novartis
Corporate Intellectual Property.
One Health Plaza – Building 430
East Hanover, NJ 07936-1080
(862)778-7801

JJB/dd

Encls.: Form PTO 1050 (2)
copy of Declaration
copies of pages 11, 24, 25, 26, 27 and 28
postcard

Date: May 22, 2003



Joseph W. Boroyian
Agent for Patentees
Reg. No. 26,631

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 6,465,504 B1
DATED: : OCTOBER 15, 2002
INVENTOR(S) : RENE LATTMANN ET AL

It is certified that there are errors in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Title page

Item (75) should read:

-- (75) Inventors: René Lattmann, Binningen; Pierre Acklin, Basel, both of (CH) --.

Item (30) should read:

-- (30) Foreign Application Priority Data
Jun. 25, 1996 (CH)1593/96 --.

Column 7

Line 63 should read:

-- alkyl, halo-lower alkyl, lower alkoxy or nitrile; R₆ and --.

Column 8

Line 10 should read:

-- formula II in which --.

MAILING ADDRESS OF SENDER:

Joseph J. Borovian
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7801

PATENT NO. 6,465,504 B1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 6,465,504 B1
DATED: : OCTOBER 15, 2002
INVENTOR(S) : RENE LATTMANN ET AL

It is certified that there are errors in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 16

Last line should read:

-- [1,3]oxazin-4-one are boiled under reflux for 5 h with 1.7 g --.

Column 17

Line 17 should read:

-- dimethylaminobenzyl)-1H-[1,2,4]triazole remains as colorless --.

Line 58 should read:

-- remains as colorless crystals of m.p. 268-269° C. --.

Column 18

Line 24 should read:

--2.0 g of ethyl [3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol- --.

MAILING ADDRESS OF SENDER:

Joseph J. Borovian
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7801

PATENT NO. 6,465,504 B1

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO : 6,465,504 B1
DATED: : OCTOBER 15, 2002
INVENTOR(S) : RENE LATTMANN ET AL

It is certified that there are errors in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 19

Line 34 should read:

-- ethoxy)ethyl]acetamide remains as colorless crystals of m.p --.

Line 42 should read:

-- yl]acetate (Example2) and 1.0 g of N,N-bis(2-hydroxyethyl) --.

Line 53 should read:

-- 2H), 4.9 (s, 2H), 7.0 (m, 4H), 7.4 (m, 3H), 7.95 (d, 1H), 8.1 (t, 1H), 11.0 --.

MAILING ADDRESS OF SENDER:

Joseph J. Borovian
Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7801

PATENT NO. 6,465,504 B1